Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.

Owen RG, McCarthy H, Rule S, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Aurran-Schleinitz T, Cheson BD, Walter H, Greenwald D, Chen DY, Frigault MM, Hamdy A, Izumi R, Patel P, Wei H, Lee SK, Mittag D, Furman RR.

Lancet Haematol. 2020 Feb;7(2):e112-e121. doi: 10.1016/S2352-3026(19)30210-8. Epub 2019 Dec 19.

PMID:
31866281
2.

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Wilson JN, Jenner MW, Cook G, Kaiser MF, Drayson MT, Owen RG, Russell NH, Gregory WM, Morgan GJ; UK NCRI Haematological Oncology Clinical Studies Group.

Lancet Haematol. 2019 Dec;6(12):e616-e629. doi: 10.1016/S2352-3026(19)30167-X. Epub 2019 Oct 14.

3.

Exploratory Study of MYD88 L265P, Rare NLRP3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome.

Pathak S, Rowczenio DM, Owen RG, Doody GM, Newton DJ, Taylor C, Taylor J, Cargo C, Hawkins PN, Krause K, Lachmann HJ, Savic S.

Arthritis Rheumatol. 2019 Dec;71(12):2121-2125. doi: 10.1002/art.41030. Epub 2019 Oct 14.

PMID:
31268627
4.

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.

Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG.

Haematologica. 2019 Jul;104(7):1440-1450. doi: 10.3324/haematol.2018.202200. Epub 2019 Feb 7.

5.

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group.

Lancet Oncol. 2019 Jan;20(1):57-73. doi: 10.1016/S1470-2045(18)30687-9. Epub 2018 Dec 14.

6.

Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.

Cohen OC, Counsell N, Rabin N, Popat R, Owen RG, Popova B, Schofield O, Clifton-Hadley L, Lyons-Lewis J, Rawstron A, Spence C, de Tute RM, Hughes D, Moore S, Smith P, Yong KL.

Br J Haematol. 2019 Jun;185(5):948-951. doi: 10.1111/bjh.15649. Epub 2018 Nov 20. No abstract available.

PMID:
30460696
7.

Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e89-e97. doi: 10.1016/j.bbmt.2018.11.001. Epub 2018 Nov 5.

PMID:
30408566
8.

Subclonal TP53 copy number is associated with prognosis in multiple myeloma.

Shah V, Johnson DC, Sherborne AL, Ellis S, Aldridge FM, Howard-Reeves J, Begum F, Price A, Kendall J, Chiecchio L, Savola S, Jenner MW, Drayson MT, Owen RG, Gregory WM, Morgan GJ, Davies FE, Houlston RS, Cook G, Cairns DA, Jackson G, Kaiser MF; National Cancer Research Institute Haematology Clinical Studies Group.

Blood. 2018 Dec 6;132(23):2465-2469. doi: 10.1182/blood-2018-06-857250. Epub 2018 Oct 29.

9.

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K.

Blood. 2018 Nov 15;132(20):2154-2165. doi: 10.1182/blood-2018-05-849893. Epub 2018 Sep 4.

10.

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.

Yadav P, Cockwell P, Cook M, Pinney J, Giles H, Aung YS, Cairns D, Owen RG, Davies FE, Jackson GH, Child JA, Morgan GJ, Drayson MT.

BMC Nephrol. 2018 Jul 13;19(1):178. doi: 10.1186/s12882-018-0962-x.

11.

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.

Royle KL, Gregory WM, Cairns DA, Bell SE, Cook G, Owen RG, Drayson MT, Davies FE, Jackson GH, Morgan GJ, Child JA.

Br J Haematol. 2018 Sep;182(6):816-829. doi: 10.1111/bjh.15459. Epub 2018 Jul 9.

12.

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.

Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C.

Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.

13.

Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study.

Rawstron AC, Ssemaganda A, de Tute R, Doughty C, Newton D, Vardi A, Evans PAS, Stamatopoulos K, Owen RG, Lightfoot T, Wakeham K, Karabarinde A, Asiki G, Newton R.

Lancet Haematol. 2017 Jul;4(7):e334-e340. doi: 10.1016/S2352-3026(16)30192-2.

14.

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.

Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, Begum DB, Proszek PZ, Jones JR, Pawlyn C, Savola S, Jenner MW, Drayson MT, Owen RG, Houlston RS, Cairns DA, Gregory WM, Cook G, Davies FE, Jackson GH, Morgan GJ, Kaiser MF.

Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.

15.

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.

Jones JR, Cairns DA, Gregory WM, Collett C, Pawlyn C, Sigsworth R, Striha A, Henderson R, Kaiser MF, Jenner M, Cook G, Russell NH, Williams C, Pratt G, Kishore B, Lindsay J, Drayson MT, Davies FE, Boyd KD, Owen RG, Jackson GH, Morgan GJ.

Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114.

16.

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.

Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ.

Clin Cancer Res. 2016 Dec 1;22(23):5783-5794. Epub 2016 May 27.

17.

A fatal case of transplantation-mediated alloimmune thrombocytopenia following liver transplantation.

Hill QA, Harrison LC, Padmakumar AD, Owen RG, Prasad KR, Lucas GF, Tachtatzis P.

Hematology. 2017 Apr;22(3):162-167. doi: 10.1080/10245332.2016.1240392. Epub 2016 Oct 21.

PMID:
27764999
18.

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM.

JAMA Oncol. 2017 Jan 1;3(1):28-35. doi: 10.1001/jamaoncol.2016.3160.

19.

Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia.

Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, Varettoni M, Dimopoulos MA, Treon SP, Kastritis E.

Br J Haematol. 2016 Oct;175(1):77-86. doi: 10.1111/bjh.14196. Epub 2016 Jul 5.

20.

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.

de Tute RM, Rawstron AC, Gregory WM, Child JA, Davies FE, Bell SE, Cook G, Szubert AJ, Drayson MT, Jackson GH, Morgan GJ, Owen RG.

Haematologica. 2016 Feb;101(2):e69-71. doi: 10.3324/haematol.2015.128215. Epub 2015 Oct 15. No abstract available.

21.

Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.

Landgren O, Owen RG.

Cytometry B Clin Cytom. 2016 Jan;90(1):14-20. doi: 10.1002/cyto.b.21273. Epub 2015 Dec 22. Review.

22.

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.

Rawstron AC, de Tute RM, Haughton J, Owen RG.

Cytometry B Clin Cytom. 2016 Jan;90(1):54-60. doi: 10.1002/cyto.b.21271. Epub 2015 Dec 21. Review.

23.

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ.

Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997.

24.

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.

Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, Cook G, Jackson GH, Morgan GJ, Child JA, Owen RG.

Blood. 2015 Mar 19;125(12):1932-5. doi: 10.1182/blood-2014-07-590166. Epub 2015 Feb 2.

25.

Prolonged remission of marginal zone lymphoma in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor agents.

Donaldson SL, Owen RG, McGonagle DG.

J Rheumatol. 2014 Dec;41(12):2496-7. doi: 10.3899/jrheum.140725. No abstract available.

PMID:
25452189
26.

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.

Boyle EM, Proszek PZ, Kaiser MF, Begum D, Dahir N, Savola S, Wardell CP, Leleu X, Ross FM, Chiecchio L, Cook G, Drayson MT, Owen RG, Ashcroft JM, Jackson GH, Anthony Child J, Davies FE, Walker BA, Morgan GJ.

Genes Chromosomes Cancer. 2015 Feb;54(2):91-8. doi: 10.1002/gcc.22222. Epub 2014 Oct 7.

27.

Bone marrow assessment in asymptomatic IgM monoclonal gammopathies - reply to Varettoni et al.

Owen RG, Pratt G, Auer RL, Flatley R, Kyriakou C, Lunn MP, Matthey F, McCarthy H, McNicholl FP, Rassam SM, Wagner SD, Streetly M, D'Sa S; British Committee for Standards in Haematology.

Br J Haematol. 2015 Jan;168(2):302-3. doi: 10.1111/bjh.13095. Epub 2014 Aug 27. No abstract available.

PMID:
25160738
28.

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.

Landgren O, Gormley N, Turley D, Owen RG, Rawstron A, Paiva B, Barnett D, Arroz M, Wallace P, Durie B, Yuan C, Dogan A, Stetler-Stevenson M, Marti GE.

Am J Hematol. 2014 Dec;89(12):1159-60. doi: 10.1002/ajh.23831. No abstract available.

29.

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP.

Blood. 2014 Aug 28;124(9):1404-11. doi: 10.1182/blood-2014-03-565135. Epub 2014 Jul 15. Review.

30.

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.

Hill QA, Rawstron AC, de Tute RM, Owen RG.

Blood. 2014 Aug 21;124(8):1296-9. doi: 10.1182/blood-2014-04-566521. Epub 2014 Jun 17.

PMID:
24939658
31.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, Davies FE, Cavo M, Drayson MT, Morgan GJ.

Blood. 2014 May 29;123(22):3414-9. doi: 10.1182/blood-2013-12-542662. Epub 2014 Apr 14.

PMID:
24733348
32.

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.

Jackson GH, Morgan GJ, Davies FE, Wu P, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Boyd KD, Osborne WL, Cook G, Child JA.

Br J Haematol. 2014 Jul;166(1):109-17. doi: 10.1111/bjh.12861. Epub 2014 Mar 27.

PMID:
24673708
33.

Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.

Owen RG, Pratt G, Auer RL, Flatley R, Kyriakou C, Lunn MP, Matthey F, McCarthy H, McNicholl FP, Rassam SM, Wagner SD, Streetly M, D'Sa S; British Committee for Standards in Haematology.

Br J Haematol. 2014 May;165(3):316-33. doi: 10.1111/bjh.12760. Epub 2014 Feb 15. No abstract available.

PMID:
24528152
34.

Resolution of methotrexate-induced Epstein-Barr virus-associated mucocutaneous ulcer.

Sadasivam N, Johnson RJ, Owen RG.

Br J Haematol. 2014 Jun;165(5):584. doi: 10.1111/bjh.12743. Epub 2014 Jan 24. No abstract available.

PMID:
24456137
35.

Reply to M. Roschewski et al.

Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG.

J Clin Oncol. 2014 Feb 10;32(5):476-7. doi: 10.1200/JCO.2013.53.0980. Epub 2014 Jan 13. No abstract available.

PMID:
24419132
36.

Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.

Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Cook G, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA.

Clin Cancer Res. 2013 Nov 1;19(21):6030-8. doi: 10.1158/1078-0432.CCR-12-3211. Epub 2013 Aug 30.

37.

The impact of response on bone-directed therapy in patients with multiple myeloma.

Larocca A, Child JA, Cook G, Jackson GH, Russell N, Szubert A, Gregory WM, Brioli A, Owen RG, Drayson MT, Wu P, Palumbo A, Boccadoro M, Davies FE, Morgan GJ.

Blood. 2013 Oct 24;122(17):2974-7. doi: 10.1182/blood-2013-04-498139. Epub 2013 Aug 23.

PMID:
23974194
38.

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, Ross FM, Cook G, Jackson GH, Morgan GJ, Owen RG.

J Clin Oncol. 2013 Jul 10;31(20):2540-7. doi: 10.1200/JCO.2012.46.2119. Epub 2013 Jun 3. Erratum in: J Clin Oncol. 2013 Dec 1;31(34):4383.

PMID:
23733781
39.

Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells.

de Tute RM, Rawstron AC, Owen RG.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):211-3. doi: 10.1016/j.clml.2013.02.018. Epub 2013 Mar 22.

PMID:
23523273
40.

Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.

Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, Seymour JF, Patmore RD, Wright D, Morel P, Dilhuydy MS, Willoughby S, Dartigeas C, Malphettes M, Royer B, Ewings M, Pratt G, Lejeune J, Nguyen-Khac F, Choquet S, Owen RG.

J Clin Oncol. 2013 Jan 20;31(3):301-7. doi: 10.1200/JCO.2012.44.7920. Epub 2012 Dec 10.

PMID:
23233721
41.

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP; VIth International Workshop on Waldenström macroglobulinaemia.

Br J Haematol. 2013 Jan;160(2):171-6. doi: 10.1111/bjh.12102. Epub 2012 Nov 15.

PMID:
23150997
42.

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Blood. 2012 Jun 7;119(23):5374-83. doi: 10.1182/blood-2011-11-392522. Epub 2012 Apr 12.

PMID:
22498739
43.

Waldenstrom macroglobulinemia with a durable clinical response to epoetin beta.

Parrish C, Owen RG.

Leuk Lymphoma. 2012 Sep;53(9):1811-3. doi: 10.3109/10428194.2012.658795. Epub 2012 Mar 1. No abstract available.

PMID:
22260157
44.

Progression of IgA gammopathy to myeloma following infliximab treatment for pyoderma gangrenosum.

Shareef MS, Munro LR, Owen RG, Highet AS.

Clin Exp Dermatol. 2012 Mar;37(2):146-8. doi: 10.1111/j.1365-2230.2011.04219.x. Epub 2011 Nov 21.

PMID:
22103549
45.

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.

Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Haematologica. 2012 Mar;97(3):442-50. doi: 10.3324/haematol.2011.043372. Epub 2011 Nov 4.

46.

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Blood. 2012 Jan 5;119(1):7-15. doi: 10.1182/blood-2011-06-357038. Epub 2011 Oct 20.

PMID:
22021371
47.

Is colonoscopy still mandatory after a CT diagnosis of left-sided diverticulitis: can colorectal cancer be confidently excluded?

Lau KC, Spilsbury K, Farooque Y, Kariyawasam SB, Owen RG, Wallace MH, Makin GB.

Dis Colon Rectum. 2011 Oct;54(10):1265-70. doi: 10.1097/DCR.0b013e31822899a2.

PMID:
21904141
48.

Heterogeneity of histological transformation events in Waldenström's macroglobulinemia (WM) and related disorders.

Owen RG, Bynoe AG, Varghese A, de Tute RM, Rawstron AC.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):176-9. doi: 10.3816/CLML.2011.n.042.

PMID:
21856554
49.

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.

Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE; National Cancer Research Institute Haematological Oncology Clinical Studies Group.

Lancet Oncol. 2011 Aug;12(8):743-52. doi: 10.1016/S1470-2045(11)70157-7. Epub 2011 Jul 21.

50.

Defining IgM multiple myeloma.

Owen RG, Feyler S, O'Connor SJ, Bond LR, de Tute RM, Rawstron AC.

Am J Hematol. 2011 Aug;86(8):717; author reply 718-9. doi: 10.1002/ajh.22061. No abstract available.

Supplemental Content

Support Center